Sugi Predict

Sugi Predict / Compounds / SCHEMBL215366

SCHEMBL215366

SCHEMBL215366

Cc1ccc(Br)cc1NC(=O)c1nc[nH]c1C(=O)Nc1nc2ccc(OCCN3CCCC3)cc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ ACHE P22303 4/20 0.43
▸ CHEK2 O96017 2/20 0.42
▸ KDR P35968 2/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ BRAF P15056 2/20 0.39
▸ PIR O00625 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ HSF1 Q00613 1/20 0.39
▸ GAA P10253 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ FLT3 P36888 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215871 0.96 LMNA (0.43) LMNAMAPK1HIF1AACHECHEK2
SCHEMBL3327359 0.96 LMNA (0.43) LMNAMAPK1HIF1AACHECHEK2
SCHEMBL14222350 0.91 LMNA (0.43) LMNAMAPK1HIF1AACHECHEK2
SCHEMBL216099 0.90 MAPT (0.39) LMNAMAPK1HIF1AKDRKMT2A
SCHEMBL213924 0.90 ALDH1A1 (0.40) LMNACHEK2KMT2ASMN1; SMN2KDM4E
SCHEMBL213711 0.89 ALDH1A1 (0.38) LMNAMAPK1HIF1AKDRKMT2A
Hydrochloric Acid SCHEMBL213385 0.89 MAPT (0.38) LMNAMAPK1HIF1AKDRKMT2A
SCHEMBL215580 0.88 DRD3 (0.38) MAPK1KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL216395 0.88 ACHE (0.47) LMNAMAPK1HIF1AACHECHEK2
SCHEMBL215715 0.87 LMNA (0.43) LMNAMAPK1HIF1AACHECHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 — — EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 LMNA 4821/4885MAPK1 354/4885HIF1A 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.